Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc.
Company type	Public
Traded as	Nasdaq: ARCT
Industry	Pharmaceutical industry
Founded	2013
Founder	Joseph Payne and Pad Chivukula
Headquarters	San Diego, California, US
Key people	Joseph Payne (president, CEO & director of the board); Padmanabh Chivukula (CSO & COO); Andrew Sassine (CFO);
Products	ARCT-810 for treatment of OTCD; received FDA Orphan Drug Status on 27 July 2019; Phase 1 Clinical Trials in Healthy Volunteers Initiated on 05 June 2020, ARCT-021 Vaccine for COVID-19; Phase 1/2 Initiated 22 July 2020, Phase 2 Initiated 9 January 2021
Revenue	$21 Million(2019)
Number of employees	124
Website	www.arcturusrx.com

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021^[update], vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase.^[2]

^ "Arcturus Therapeutics Holdings Revenue 2012-2021 | ARCT".
^ Cite error: The named reference :0 was invoked but never defined (see the help page).